Beam Therapeutics (BEAM) Stock Price, News & Analysis

+0.83 (+3.49%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.33 million shs
Average Volume
1.46 million shs
Market Capitalization
$2.03 billion
P/E Ratio
Dividend Yield
Price Target

Beam Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.38 Rating Score
63.2% Upside
$40.18 Price Target
Short Interest
17.03% of Shares Sold Short
Dividend Strength
News Sentiment
0.39mentions of Beam Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$3.16 M Sold Last Quarter
Proj. Earnings Growth
From ($4.68) to ($4.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.47 out of 5 stars

Medical Sector

722nd out of 921 stocks

Biological Products, Except Diagnostic Industry

117th out of 148 stocks

BEAM stock logo

About Beam Therapeutics Stock (NASDAQ:BEAM)

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Stock Price History

BEAM Stock News Headlines

See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$377.71 million
Book Value
$11.10 per share


Free Float
Market Cap
$2.03 billion

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

BEAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price target for 2024?

13 Wall Street research analysts have issued 1-year target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $57.00. On average, they predict the company's share price to reach $40.18 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2024?

Beam Therapeutics' stock was trading at $27.22 at the beginning of the year. Since then, BEAM shares have decreased by 9.6% and is now trading at $24.62.
View the best growth stocks for 2024 here

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our BEAM earnings forecast

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) released its quarterly earnings data on Tuesday, May, 7th. The company reported ($1.21) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.21. The company had revenue of $7.40 million for the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 15.46% and a negative net margin of 37.33%. The business's revenue was down 69.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.33) earnings per share.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

Beam Therapeutics (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.21%), Sumitomo Mitsui Trust Holdings Inc. (2.89%), Nikko Asset Management Americas Inc. (2.87%), Darwin Global Management Ltd. (2.58%), Redmile Group LLC (2.28%) and Price T Rowe Associates Inc. MD (1.51%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
This page (NASDAQ:BEAM) was last updated on 5/19/2024 by Staff

From Our Partners